Remestemcel-L-rknd para la enfermedad aguda de injerto contra huésped refractaria a esteroides en pacientes

Upendra Mahat1, Donna Przepiorka2, Lola A Fashoyin-Aje1

  • 1Division of Clinical Evaluation Hematology, Office of Clinical Evaluation, Center for Biologic Evaluation and Research, US Food and Drug Administration (FDA), Silver Spring, Maryland.

JAMA
|May 21, 2025
PubMed
Resumen

No abstract available in PubMed .